幽门螺旋桿菌诊断市场按检测类型、产品类型、最终用户和技术划分－2025-2032年全球预测

预计到 2032 年，幽门螺旋桿菌诊断市场将成长至 17.7078 亿美元，复合年增长率为 10.06%。

关键市场统计数据
基准年 2024	8.2228亿美元
预计年份：2025年	9.0604亿美元
预测年份 2032	17.7078亿美元
复合年增长率 (%)	10.06%

幽门螺旋桿菌诊断的权威概述重点介绍了临床意义、诊断方法、患者诊疗路径以及在医疗保健机构中准确检测的策略重要性。

幽门螺旋桿菌是胃肠病学领域的焦点，因为它已被证实是慢性胃炎、消化性溃疡和胃癌的危险因子。因此，准确及时的诊断至关重要，它影响着治疗方法的选择、根除监测以及更广泛的公共卫生工作。目前有侵入性和非侵入性两种幽门螺旋桿菌感染诊断方法，每种方法在敏感性、特异性、週转时间和资源消耗方面各有优劣。

临床实验室和医护人员必须考虑检测的性能特征，并结合患者的临床表现、先前治疗史以及检测结果的预期用途（例如，初步诊断、确认根除或抗药性监测）。虽然分子检测近年来已与传统的组织学和培养检测相结合，但非侵入性抗原检测和呼吸检测仍然是门诊病人评估的主要手段。这些方法应用于各种医疗机构，从基层医疗诊所到大型医院系统，每个机构都有其独特的营运限制和采购优先事项。

随着诊断技术的不断发展，实验室工作流程、临床医生偏好和支付方政策之间的相互作用变得日益重要。有效的诊断策略需要统一的检体采集通讯协定、品管和临床医生培训，以确保选择和解读合适的检测方法。此外，诊断选择直接影响抗菌药物管理工作和后续临床结局，因此亟需建立临床上可靠且易于操作的诊断路径。

技术、营运和数位化变革正在改变幽门螺旋桿菌的诊断方式，并影响临床决策和市场动态。

由于分子技术的进步、照护现场设备的微型化以及非侵入性检测能力的提升，幽门螺旋桿菌的诊断格局正在迅速转变。分子平台正从集中式实验室PCR系统扩展到床边等温PCR方法和即时PCR仪，这些仪器能够同时提供幽门螺旋桿菌的检测和抗菌药物抗药性标记。同时，增强型免疫测量和高性能粪便抗原检测也在不断改进非侵入性筛检和治疗后确认方法。

同时，内视镜技术和影像增强演算法的进步提高了视觉检测能力，并实现了标靶切片检查，从而提高了诊断率。人工智慧工具正开始辅助病灶识别和手术流程标准化，加上染色和组织学技术的改进，在临床需要时，侵入性诊断的作用日益凸显。这些转变将推动更精准的治疗决策，并更好地契合抗菌药物管理的目标。

在营运层面，去中心化正在重塑采购和服务交付模式。即时侦测加快了结果出炉速度，并可整合到门诊工作流程中。数位医疗、远端医疗和实验室互联互通的整合也支持更顺畅的结果共用和后续跟进，从而提高根除通讯协定的依从性。这些技术和营运方面的转变创造了新的商业性和临床机会，同时也带来了验证、品质保证和报销方面的新挑战。

评估2025年美国关税如何改变了幽门螺旋桿菌诊断的供应链、生产决策和筹资策略

美国将于2025年实施关税，将对诊断生态系统产生多方面的影响，包括组件采购、定价策略和供应链架构。关税主导的成本压力迫使进口耗材、试剂和分析仪组件的价格上涨，促使许多製造商和临床实验室重新评估其供应商关係和库存管理实践。因此，采购团队正在延长前置作业时间并增加缓衝库存，以降低潜在的供应中断风险。

在产品层面，关税促使大量耗材和检测试剂套件在本地生产或外包。一些诊断公司已采取措施应对，例如认证更多国内製造外包或将组装迁至受贸易壁垒影响较小的地区。虽然这些策略倡议旨在保障供应的连续性并降低关税波动带来的风险，但它们需要对品质系统、监管许可和供应商审核进行投资。

医疗机构面临着相互矛盾的压力：既要维持临床检验的检测流程，也要应对预算限制。实验室和医院正在仔细评估分析仪的单次检测成本和总拥有成本，权衡资本投资与试剂依赖性以及服务合约条款。规模较小的诊所和门诊中心正在考虑透过集团采购组织和长期供应协议进行集中采购，以确保获得必要的诊断服务。

随着对国产检测产品来源和可追溯性的要求日益提高，监管合规和文件记录变得癒合重要。优先考虑供应链多元化的供应商强调透明的品管和加快监管申报流程，从而缩短替代产品的上市时间。总体而言，关税环境正在推动製造、采购和临床应用路径的结构性变革，迫使相关人员在提升韧性投资和控制短期营运成本之间寻求平衡。

基于细分市场的洞察，揭示了检测类型、产品类型、最终用户需求和技术类别在塑造诊断应用和投资重点方面的交汇点。

透过精细化的市场细分，我们可以洞察临床需求与技术能力的交会点，从而找到最具回报的策略投资方向。无论检测类型如何，组织检测仍然是侵入性诊断流程的基石，通常采用苏木精-伊红染色和用于病原体可视化的专用染色剂。分子检测技术正在不断发展，从用于快速床边检测的等温扩增，到用于高灵敏度检测的传统聚合酵素链锁反应，再到用于定量和抗药性标记鑑定的即时PCR。快速尿素酶检测在内镜实验室中仍发挥效用，目前常用的检测方法包括Clo检测和PyloriTek检测，这些检测方法优先考虑速度和易于判读的特性。血清学检测在流行病学研究和特定临床情况下仍发挥作用，但作为治疗后确认的首选方法，其主要手段是酵素结合免疫吸附试验和横向流动化验。透过酵素免疫分析法和侧向流动免疫检测进行粪便抗原检测，支持非侵入性诊断和根除检验，尿素呼气试验（有 13C 和 14C 变体）仍然是一种高度准确的非侵入性选择，常用于基层医疗和专科机构。

在评估产品类型时，由于套件、试剂和试纸的持续需求，耗材在常规检测中占据主导地位。试剂套件包括用于分子检测的PCR试剂套件、专为特定操作定制的快速尿素酶检测试剂盒、针对批量检测优化的血清检测套组、适用于门诊检体处理的粪便抗原检测套组以及与呼气分析仪兼容的尿素呼吸检测套件。分析设备包括呼气检测套组、免疫检测分析仪和PCR仪，其通量、自动化程度和连接方式各不相同。内视镜系统对于侵入性诊断和治疗性介入至关重要，因此推动了对整合影像和切片检查功能的需求。

终端使用者引入的操作细节会影响产品偏好和购买行为。包括社区健康中心和门诊诊所在内的行动医疗中心优先考虑快速、易于操作的非侵入性检测和耐用的即时检测解决方案。无论是初级诊所还是专科诊所，都需要在成本和临床疗效之间取得平衡，以支持常规筛检和追踪。诊断实验室分为商业实验室和参考实验室，它们倾向于使用高通量分子仪器和自动化免疫检测平台，以实现可扩展的检测和多重分析能力。包括大型三级医院和小型区域医疗机构在内的医院，需要将强大的内视镜功能与一系列分析仪和耗材结合，以支援住院和门诊工作流程。

技术领域区分了侵入性方法（例如培养、组织学和快速尿素酶试验）和无创技术（例如抗原检测、呼吸检测、分子检测和血清学检测）。值得注意的是，呼吸检测的定义涵盖了粪便抗原检测和尿素呼吸检测，并结合了它们在临床应用中的具体情况，这反映了非侵入性样本类型和分析平台在实际操作部署中的重迭性。这种细緻的划分凸显了供应商需要根据每个最终用户群和检测环境的独特工作流程需求来客製化产品设计和商业化策略。

美洲、欧洲、中东和非洲以及亚太地区不同的诊断动态揭示了检测策略的采纳、基础设施和政策方面存在的问题。

区域动态对诊断选择、报销和应用路径有显着影响，美洲、欧洲、中东和非洲以及亚太地区呈现出清晰的模式。在美洲，成熟的实验室网路和先进的报销机制有利于高灵敏度分子检测和整合分析仪平台的应用。中心实验室和参考检测服务支援复杂的分子检测流程，而门诊和日间诊疗中心则越来越多地采用即时检测（POC​​）解决方案以缩短治疗时间。该地区也日益重视抗菌药物管理计画和治疗后确认方案，这些因素正在影响检测选择。

欧洲、中东和非洲的市场呈现异质性，监管环境各异，医疗基础设施也不断变化。一些国家正在迅速推广非侵入性检测和呼气分析仪，而其他国家则由于临床医生的偏好和资源限制，仍然依赖传统的组织检测和内视镜诊断。这些市场的报销政策和国家指南可能会显着改变商业性格局，因此需要区域性的证据收集和相关人员的参与才能促进技术的普及应用。

亚太地区的情况十分复杂，某些次区域疾病高发，国内製造业产能不断成长，技术应用也日新月异。粪便抗原检测和尿素呼气试验等非侵入性诊断方法在基层医疗中尤其重要，因此在分子平台和耗材本地化生产方面都投入了大量资金。私人医疗保健的成长和诊断实验室网路的扩张正在加速自动化分析仪和多重分子检测技术的应用，而一些国家的政府公共卫生工作则优先考虑筛检和消除项目，这影响了采购和实施策略。

从竞争对手观点分析幽门螺旋桿菌诊断领域的竞争定位，并着重于产品效能、伙伴关係模式、供应链韧性和临床证据策略。

幽门螺旋桿菌诊断领域的竞争格局有利于那些能够将强大的检测性能、可靠的供应链、监管专业知识和清晰的临床价值命题主张相结合的公司。成熟的仪器製造商凭藉装置量、服务网路和用于结果管理的整合软体保持优势，而敏捷的分子生物学公司则凭藉快速的检测开发週期和抗药性检测能力脱颖而出。能够证明其检测性能在不同检体类型中具有可重复性，并投资于品质认证的套件和试剂供应商，更有可能赢得与商业实验室和医院实验室的长期合约。

随着企业寻求提供能够简化实验室客户实施流程的端到端解决方案，仪器供应商与侦测开发人员之间的策略伙伴关係和共同开发契约正变得越来越普遍。能够在满足严格品质标准的同时扩大生产规模的契约製造製造商是宝贵的合作伙伴，尤其是在关税压力和供应链韧性面临挑战的时期。此外，能够提供全面的培训、技术支援以及将检测结果整合到电子健康记录中的连接解决方案的公司也越来越受到机构买家的青睐。

专注于多重检测、抗药性基因分型和简化样本到结果工作流程的创新产品线正日益受到临床医生和采购团队的青睐。投资于严谨的临床检验研究并与关键意见领袖合作以产生真实世界证据的公司将巩固其市场地位。最后，积极管理监管申报并在关键地区证明合规性的公司将减少实施阻力并加速商业化部署。

为诊断试剂生产商、实验室和医疗系统提供切实可行的策略建议，以加速幽门螺旋桿菌检测的推广应用、提高应对能力并最大限度地发挥其临床价值。

产业领导者应考虑采取一系列切实可行的措施，以充分利用新兴的诊断趋势，同时降低营运风险。首先，应优先投资于非侵入性分子检测和高性能抗原检测，以简化工作流程并减少对侵入性操作的依赖，同时确保这些检测方法已通过验证，可用于其预期的临床用途。其次，应实现供应链多元化，增加供应商数量，并评估近岸外包和区域製造伙伴关係，以降低贸易中断带来的风险并缩短前置作业时间。

第三，我们将制定一项支付方和医疗系统参与策略，阐明准确诊断的临床和经济价值，包括检测在减少不必要的抗生素使用和预防后续併发症的作用。第四，我们将开发整合解决方案，将分析仪、耗材套件和数位连接结合，以增强数据流、实现品管并支援临床医生的决策。第五，我们将投资于抗菌药物抗药性检测能力和相应的临床医生培训，以加强抗菌药物管理并提供可操作的治疗指南。

第六，我们将与内视镜系统供应商和实验室自动化合作伙伴建立策略伙伴关係，以建构与医疗机构工作流程相契合的综合诊断路径。第七，我们将积极拓展不同地区的市场，重点关注监管合规性，并透过多中心检验研究快速取得证据。最后，我们将推出灵活的商业模式，例如试剂租赁、订阅定价和结果挂钩合同，以满足买方偏好，并在引进週期内与客户共用风险。

一项综合性的混合方法研究途径，结合专家访谈、工作流程分析、监管审查和技术评估，检验诊断见解和影响。

本分析所依据的研究采用了混合方法，将一手定性研究成果与二手证据综合和技术评估相结合。一手研究包括对临床医生、实验室主任、采购负责人和行业高管进行结构化访谈，以了解实际的诊断工作流程、采购理由和未满足的需求。此外，还进行了现场考察和工作流程图绘製，以更深入地了解检体处理、结果报告以及照护现场和检测系统整合等环节。

二级研究涵盖了同行评审文献、临床指南、监管文件和技术产品规格，以检验检测性能特征并比较不同技术平台。技术评估包括分析灵敏度、特异性、週转时间、通量和操作规模。此外，还审查了主要司法管辖区的监管路径，以确定证据要求和核准时间表。

本调查方法采用资料三角测量法来调和一手资讯和二手资讯之间的差异，并确保结论的稳健性。在条件允许的情况下，我们使用临床检验研究和真实世界性能数据来评估诊断效用及其对不同终端使用者环境的适用性。本研究方法也承认其局限性，例如测试实施中可能存在的差异以及区域指南的不同，并强调研究结果旨在支持策略决策，而非提供强制性的临床指导。

总结而言，诊断创新、营运韧性和临床管理之间的策略性融合将塑造幽门螺旋桿菌检测的未来。

幽门螺旋桿菌诊断正处于曲折点，分子技术的进步、非侵入性检测方法的改进以及临床路径的不断完善，使得患者管理更加精准。整个生态系统中的相关人员——包括製造商、实验室、临床医生和医疗保健系统——必须适应技术进步，同时应对供应链的复杂性和不断变化的报销机制。产品设计、证据产生和最终用户需求之间的策略性协调，对于充分发挥下一代诊断技术的临床和商业性潜力至关重要。

未来的成功取决于能否提供临床相关且运作永续的解决方案，这些方案需与诊疗路径相整合，并支援抗菌药物管理。透过优先考虑采购的韧性、投资于经临床检验的技术，并以清晰的提案主张与支付方和医疗服务提供者建立联繫，各机构可以改善患者预后并获得竞争优势。不断变化的市场环境为那些将卓越技术能力与切实可行的商业化策略相结合，并能应对区域和终端用户差异的公司提供了巨大的机会。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 透过整合人工智慧增强型内视镜成像平台，实现幽门螺旋桿菌的即时检测和诊断。
• 扩大照护现场诊断检测规模，用于快速幽门螺旋桿菌抗生素抗药性分析
• 在基层医疗中越来越多地采用非侵入性的 13C-尿素呼吸检测进行幽门螺旋桿菌早期筛检
• 开发一种结合幽门螺旋桿菌毒力因子检测和生物标记分析的多重血清学检测方法
• 数位健康平台的出现以及幽门螺旋桿菌诊断结果在患者管理中的整合
• 加强诊断设备製造商与胃肠病诊所之间的合作，以简化幽门螺旋桿菌检测流程。
• 监管部门的核准加速了次世代定序在幽门螺旋桿菌菌株鑑定中的应用
• 在资源匮乏的环境中，对粪便抗原免疫检测的需求日益增长，这有助于幽门螺旋桿菌的诊断。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 幽门螺旋桿菌诊断市场（依检测类型划分）

• 组织学
  • 苏木精-伊红染色
  • 特殊染色
• 分子检测
  • 等温扩增
  • 聚合酵素链锁反应
  • 即时聚合酵素链锁反应
• 快速尿素酶试验
  • 黑检
  • Pyrolitec 测试
• 血清学检测
  • 酵素结合免疫吸附试验
  • 横向流动化验
• 粪便抗原检测
  • 酵素免疫分析法
  • 侧向流动免疫检测
• 尿素呼气试验
  • 13C-尿素呼气试验
  • 14C-尿素呼气试验

9. 幽门螺旋桿菌诊断市场（依产品类型划分）

• 消耗品
  • 套件
    • PCR试剂套件
    • 快速尿素酶检测套组
    • 血清检测套组
    • 粪便抗原检测套组
    • 尿素呼吸检测套件
  • 试剂
  • 测试条
• 装置
  • 分析器
    • 呼吸检测分析仪
    • 免疫检测分析仪
    • PCR装置
  • 内视镜系统

第十章 幽门螺旋桿菌诊断市场（依最终用户划分）

• 门诊治疗中心
  • 社区健康中心
  • 门诊部
• 诊所
  • 基层医疗诊所
  • 专科诊所
• 诊断实验室
  • 商业实验室
  • 参考实验室
• 医院
  • 大型医院
  • 小型医院

第十一章 幽门螺旋桿菌诊断市场（依技术划分）

• 侵入性
  • 文化
  • 组织学
  • 快速尿素酶试验
• 非侵入性
  • 抗原检测
  • 呼吸检测
    • 粪便抗原检测
    • 尿素呼吸检测
  • 分子
  • 血清

第十二章 幽门螺旋桿菌诊断市场（依地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章 幽门螺旋桿菌诊断市场（按组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 各国幽门螺旋桿菌诊断市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Danaher Corporation
  • bioMerieux SA
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • DiaSorin SpA
  • Bio-Rad Laboratories, Inc.
  • Fujirebio Inc.
  • Sekisui Medical Co., Ltd.

The Helicobacter Pylori Diagnostics Market is projected to grow by USD 1,770.78 million at a CAGR of 10.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 822.28 million
Estimated Year [2025]	USD 906.04 million
Forecast Year [2032]	USD 1,770.78 million
CAGR (%)	10.06%

A definitive overview of Helicobacter pylori diagnostics highlighting clinical implications, diagnostic modalities, patient pathways, and the strategic importance of accurate testing across care settings

Helicobacter pylori remains a central concern in gastrointestinal medicine due to its established role in chronic gastritis, peptic ulcer disease, and as a risk factor for gastric malignancy. Accurate, timely diagnosis is therefore a clinical imperative that affects therapy selection, eradication monitoring, and broader public health efforts. Diagnostics for H. pylori span invasive and noninvasive approaches, each offering distinct trade-offs between sensitivity, specificity, turnaround time, and resource intensity.

Clinical laboratories and care providers must consider test performance characteristics in the context of patient presentation, prior treatment history, and the intended use of results-whether for initial diagnosis, confirmation of eradication, or surveillance for resistance. Recent years have seen the integration of molecular methods alongside traditional histology and culture, while noninvasive antigen and breath tests remain central to outpatient evaluation. These modalities are deployed across varied settings from primary care clinics to large hospital systems, with each setting imposing unique operational constraints and procurement priorities.

As diagnostics evolve, the interplay between laboratory workflows, clinician preferences, and payer policies becomes increasingly consequential. Effective diagnostic strategies require harmonization of specimen collection protocols, quality controls, and clinician education to ensure appropriate test selection and interpretation. Furthermore, diagnostic choice directly influences antibiotic stewardship efforts and downstream clinical outcomes, reinforcing the need for diagnostic pathways that are both clinically robust and operationally feasible.

Transformative technological, operational, and digital shifts reshaping Helicobacter pylori diagnostics with implications for clinical decision making and market dynamics

The diagnostic landscape for Helicobacter pylori is undergoing a rapid transformation driven by advances in molecular technologies, point-of-care instrument miniaturization, and improved noninvasive testing performance. Molecular platforms are expanding from centralized laboratory PCR systems to near-patient isothermal approaches and real-time PCR instruments that provide both detection and antimicrobial resistance markers. At the same time, enhanced immunoassays and high-performance stool antigen tests are refining noninvasive screening and post-treatment confirmation.

Concurrently, endoscopy technology and image-enhancement algorithms are improving visual detection and enabling targeted biopsies that increase diagnostic yield. Artificial intelligence tools are beginning to support lesion recognition and procedural standardization, which, together with enhanced staining and histological techniques, strengthen the role of invasive diagnostics where clinically indicated. These shifts facilitate more precise therapeutic decisions and better alignment with stewardship goals.

Operationally, the movement toward decentralization is reshaping procurement and service delivery. Point-of-care tests reduce time-to-result and can be integrated into ambulatory workflows, while analyzer equipment continues to add throughput and multiplexing capabilities. The convergence of digital health, telemedicine, and laboratory connectivity also supports more seamless result sharing and follow-up, thereby improving adherence to eradication protocols. Taken together, these technological and operational shifts create new commercial and clinical opportunities while raising fresh challenges around validation, quality assurance, and reimbursement.

Assessing how the 2025 United States tariff measures have reshaped supply chains, manufacturing decisions, and procurement strategies across Helicobacter pylori diagnostics

The introduction of United States tariffs in 2025 has produced multifaceted impacts on the diagnostics ecosystem, influencing component sourcing, pricing strategies, and supply chain architecture. Tariff-driven cost pressures on imported consumables, reagents, and analyzer components have led many manufacturers and clinical laboratories to re-evaluate vendor relationships and inventory management practices. In turn, procurement teams have adopted longer lead times and increased buffer stocks to mitigate potential supply disruptions, which affects working capital and operational logistics.

At the product level, tariffs have incentivized local manufacturing or nearshoring initiatives for high-volume consumables and assay kits. Some diagnostic firms responded by qualifying additional domestic contract manufacturers or by relocating assembly lines to jurisdictions less affected by trade barriers. These strategic moves are intended to protect continuity of supply and to reduce exposure to tariff volatility, though they require investment in quality systems, regulatory permits, and supplier audits.

Healthcare providers face competing pressures: the need to maintain clinically validated testing algorithms while managing budgetary constraints. Laboratories and hospitals have scrutinized cost-per-test and total cost of ownership for analyzers, weighing capital acquisition against reagent dependency and service agreement terms. Smaller clinics and ambulatory centers, often with tighter margins, have had to consider consolidated purchasing through group purchasing organizations or long-term supply agreements to preserve access to essential diagnostics.

Regulatory compliance and documentation have become more salient as provenance and traceability requirements increase for domestically sourced assays. Suppliers prioritizing diversified supply chains have also emphasized transparent quality controls and rapid regulatory filings to shorten time-to-market for alternatives. Overall, the tariff environment has catalyzed structural changes across manufacturing, procurement, and clinical adoption pathways, prompting stakeholders to balance resilience investments against near-term operational costs.

Segment-driven insights revealing where test types, product formats, end-user needs, and technology categories converge to shape diagnostic adoption and investment priorities

Insights derived from granular segmentation illuminate where clinical demand converges with technological capability and where strategic investments will yield the greatest returns. Across test types, histology remains a cornerstone in invasive diagnostic workflows and is typically executed with hematoxylin and eosin staining complemented by special stains to enhance organism visualization. Molecular testing has broadened its footprint, with isothermal amplification providing rapid near-patient detection, conventional polymerase chain reaction used in reference laboratories for high-sensitivity assays, and real-time PCR offering quantitation and resistance marker identification. Rapid urease tests retain utility in endoscopy suites and are commonly available as Clo test formats and PyloriTek test variants that prioritize speed and ease of interpretation. Serology continues to play a role in epidemiologic studies and specific clinical contexts through enzyme-linked immunosorbent assays and lateral flow assays, although it is less favored for post-treatment confirmation. Stool antigen testing, delivered via enzyme immunoassays or lateral flow immunoassays, supports noninvasive diagnosis and eradication verification, while urea breath tests, available as 13C and 14C variants, remain a highly accurate noninvasive option often used in primary care and specialist settings.

When evaluating product types, consumables dominate routine testing due to the continual need for kits, reagents, and test strips. Kits span PCR kits for molecular detection, rapid urease test kits tailored for procedural use, serology kits optimized for batch testing, stool antigen test kits suitable for outpatient specimen processing, and urea breath test kits designed for breath analyzer compatibility. Instruments encompass analyzer equipment and endoscopy systems, with analyzer categories including breath test analyzers, immunoassay analyzers, and PCR instruments that vary by throughput, automation level, and connectivity. Endoscopy systems remain critical for invasive diagnostics and therapeutic interventions, driving demand for integrated imaging and biopsy capabilities.

End users introduce operational nuance that shapes product preference and purchasing behavior. Ambulatory care centers, comprised of community health centers and outpatient clinics, prioritize rapid, easy-to-administer noninvasive tests and durable point-of-care solutions. Clinics, whether primary care or specialty-focused, balance cost and clinical performance to support routine screening and follow-up. Diagnostic laboratories, split between commercial and reference laboratories, favor high-throughput molecular instruments and automated immunoassay platforms that enable scalable testing and multiplex capacity. Hospitals, including both large tertiary centers and smaller community facilities, require a hybrid mix: robust endoscopy capabilities for invasive diagnosis and a portfolio of analyzers and consumables that support inpatient and outpatient workflows.

Technology segmentation distinguishes invasive modalities such as culture, histology, and rapid urease testing from noninvasive approaches like antigen testing, breath testing, molecular assays, and serology. Notably, breath testing is contextualized to include both stool antigen test approaches and urea breath tests in applied clinical pathways, reflecting how noninvasive sample types and analytic platforms can overlap in operational deployment. This nuanced segmentation underscores the need for vendors to align product design and commercialization strategies with the distinct workflow requirements of each end-user segment and testing environment.

Regionally differentiated diagnostic dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific revealing adoption, infrastructure, and policy implications for testing strategies

Regional dynamics exert a powerful influence on diagnostic choice, reimbursement, and adoption pathways, with distinct patterns emerging across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, mature laboratory networks and advanced reimbursement frameworks favor the uptake of high-sensitivity molecular assays and integrated analyzer platforms. Centralized laboratories and reference testing services support complex molecular workflows, while ambulatory care and outpatient clinics increasingly adopt point-of-care solutions to shorten time-to-treatment. This region also emphasizes antimicrobial stewardship programs and post-treatment confirmation protocols that influence test selection.

In Europe, the Middle East & Africa, regulatory diversity and variable healthcare infrastructure create a heterogeneous marketplace. Some countries demonstrate rapid adoption of noninvasive testing and breath analyzers supported by public health screening initiatives, whereas others rely on traditional histology and endoscopy-based diagnostics due to clinician preference or resource constraints. Reimbursement policies and national guidelines in these markets can materially alter the commercial landscape, necessitating localized evidence generation and stakeholder engagement to achieve adoption.

The Asia-Pacific region presents a complex mix of high disease prevalence in certain subregions, growing domestic manufacturing capabilities, and rapid technological adoption. Noninvasive diagnostics such as stool antigen tests and urea breath tests are particularly valuable in primary care settings, and there is notable investment in both molecular platforms and local production of consumables. Private healthcare growth and expanding diagnostic laboratory networks are accelerating the adoption of automated analyzers and multiplex molecular assays, while governmental public health efforts in some countries prioritize screening and eradication programs that influence procurement and implementation strategies.

Company-level perspectives emphasizing product performance, partnership models, supply chain resilience, and clinical evidence strategies that determine competitive positioning in H pylori diagnostics

Competitive dynamics in the diagnostics landscape favor companies that combine robust assay performance with reliable supply chains, regulatory expertise, and clear clinical value propositions. Established instrument manufacturers maintain an advantage through installed base, service networks, and integrated software for result management, while agile molecular firms differentiate via rapid assay development cycles and resistance detection capabilities. Kit and reagent suppliers that can demonstrate reproducible performance across specimen types and that invest in quality certification are positioned to win long-term contracts with commercial and hospital laboratories.

Strategic partnerships and co-development agreements between instrument vendors and assay developers are increasingly common as firms seek to offer end-to-end solutions that simplify adoption for laboratory customers. Contract manufacturing organizations that can scale production while meeting stringent quality standards are valuable partners, particularly in contexts where tariff pressures and supply chain resilience are priorities. Additionally, companies that provide comprehensive training, technical support, and connectivity solutions to integrate test results into electronic health records gain traction with institutional purchasers.

Innovation pipelines focused on multiplexing, resistance genotyping, and simplified sample-to-answer workflows attract attention from both clinicians and procurement teams. Firms that invest in robust clinical validation studies and that engage with key opinion leaders to generate real-world evidence strengthen their market positioning. Finally, organizations that proactively manage regulatory filings and demonstrate compliance across major regions reduce adoption friction and accelerate commercial rollouts.

Actionable strategic recommendations for diagnostic manufacturers, laboratories, and health systems to accelerate adoption, improve resilience, and maximize clinical value of H pylori testing

Industry leaders should consider a set of pragmatic actions to capitalize on emerging diagnostic trends while mitigating operational risk. First, prioritize investment in noninvasive molecular and high-performance antigen assays that streamline workflows and reduce reliance on invasive procedures, while ensuring assays are validated for intended clinical uses. Second, diversify supply chains by qualifying additional suppliers and by evaluating nearshoring or regional manufacturing partnerships to reduce exposure to trade-related disruptions and to improve lead times.

Third, build payer and health system engagement strategies that articulate the clinical and economic value of accurate diagnostics, including the role of testing in reducing unnecessary antibiotic use and in preventing downstream complications. Fourth, develop integrated solutions that pair analyzers with consumable kits and digital connectivity to enhance data flow, enable quality controls, and support clinician decision making. Fifth, invest in antimicrobial resistance testing capabilities and corresponding clinician education to reinforce stewardship and to provide actionable therapeutic guidance.

Sixth, pursue strategic collaborations with endoscopy system providers and laboratory automation partners to create comprehensive diagnostic pathways that align with institutional workflows. Seventh, emphasize regulatory preparedness and rapid evidence generation through multicenter validation studies to facilitate market entry across diverse geographies. Finally, implement flexible commercial models-such as reagent rental, subscription-based pricing, or outcome-linked agreements-to address buyer preferences and to share risk with customers during adoption cycles.

Comprehensive mixed-methods research approach combining expert interviews, workflow analysis, regulatory review, and technology assessment to validate diagnostic insights and implications

The research underpinning this analysis employed a mixed-methods approach that integrates primary qualitative insights with secondary evidence synthesis and technical assessment. Primary research included structured interviews with clinicians, laboratory directors, procurement officers, and industry executives to capture real-world diagnostic workflows, purchasing rationales, and unmet needs. Supplemental site visits and workflow mapping provided contextual understanding of specimen handling, result reporting, and integration points for point-of-care and laboratory systems.

Secondary research encompassed peer-reviewed literature, clinical guidelines, regulatory documentation, and technical product specifications to validate assay performance characteristics and to compare technology platforms. Technology assessments evaluated analytical sensitivity, specificity, turnaround time, throughput, and operational footprint. Regulatory pathways were reviewed across major jurisdictions to identify evidence requirements and approval timelines.

Data triangulation was applied to reconcile discrepancies between primary and secondary sources and to ensure robustness of conclusions. Where available, clinical validation studies and real-world performance data informed assessments of diagnostic utility and suitability for different end-user settings. The methodology also acknowledges limitations, including potential variability in laboratory practices and regional guideline differences, and it emphasizes that insights are intended to support strategic decision-making rather than serve as prescriptive clinical guidance.

Conclusive perspective on the strategic convergence of diagnostic innovation, operational resilience, and clinical stewardship shaping the future of H pylori testing

Diagnostics for Helicobacter pylori are at an inflection point where enhanced molecular capabilities, improved noninvasive tests, and evolving clinical pathways converge to enable more precise patient management. Stakeholders across the ecosystem-manufacturers, laboratories, clinicians, and health systems-must adapt to technological advances while managing supply chain complexities and shifting reimbursement landscapes. Strategic alignment between product design, evidence generation, and end-user needs will be critical to realizing the clinical and commercial potential of next-generation diagnostics.

Looking ahead, success will hinge on the ability to deliver clinically meaningful, operationally sustainable solutions that integrate with care pathways and support antimicrobial stewardship. By prioritizing resilience in sourcing, investing in clinically validated technologies, and engaging payers and providers with clear value propositions, organizations can both improve patient outcomes and secure competitive advantage. The evolving landscape presents significant opportunities for those who combine technical excellence with pragmatic commercialization strategies that respond to regional and end-user heterogeneity.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of AI-enhanced endoscopic imaging platforms for real-time Helicobacter pylori detection and diagnostics
• 5.2. Expansion of point-of-care molecular diagnostic assays for rapid H pylori antibiotic resistance profiling
• 5.3. Growing adoption of noninvasive 13C-urea breath tests in primary care for early Helicobacter pylori screening
• 5.4. Development of multiplex serological panels combining Helicobacter pylori virulence factor detection with biomarker profiling
• 5.5. Emergence of integration between digital health platforms and H pylori diagnostic results for patient management
• 5.6. Increasing collaborations between diagnostic manufacturers and gastroenterology clinics to streamline H pylori testing workflows
• 5.7. Regulatory approval trends accelerating next-generation sequencing applications for Helicobacter pylori strain identification
• 5.8. Rising demand for stool antigen immunoassays in resource-limited settings for accessible Helicobacter pylori diagnosis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Helicobacter Pylori Diagnostics Market, by Test Type

• 8.1. Histology
  • 8.1.1. Hematoxylin And Eosin Staining
  • 8.1.2. Special Stains
• 8.2. Molecular Test
  • 8.2.1. Isothermal Amplification
  • 8.2.2. Polymerase Chain Reaction
  • 8.2.3. Real Time Polymerase Chain Reaction
• 8.3. Rapid Urease Test
  • 8.3.1. Clo Test
  • 8.3.2. PyloriTek Test
• 8.4. Serology Test
  • 8.4.1. Enzyme Linked Immunosorbent Assay
  • 8.4.2. Lateral Flow Assay
• 8.5. Stool Antigen Test
  • 8.5.1. Enzyme Immunoassay
  • 8.5.2. Lateral Flow Immunoassay
• 8.6. Urea Breath Test
  • 8.6.1. 13C Urea Breath Test
  • 8.6.2. 14C Urea Breath Test

9. Helicobacter Pylori Diagnostics Market, by Product Type

• 9.1. Consumables
  • 9.1.1. Kits
    • 9.1.1.1. PCR Kits
    • 9.1.1.2. Rapid Urease Test Kits
    • 9.1.1.3. Serology Test Kits
    • 9.1.1.4. Stool Antigen Test Kits
    • 9.1.1.5. Urea Breath Test Kits
  • 9.1.2. Reagents
  • 9.1.3. Test Strips
• 9.2. Instruments
  • 9.2.1. Analyzer Equipment
    • 9.2.1.1. Breath Test Analyzers
    • 9.2.1.2. Immunoassay Analyzers
    • 9.2.1.3. PCR Instruments
  • 9.2.2. Endoscopy Systems

10. Helicobacter Pylori Diagnostics Market, by End User

• 10.1. Ambulatory Care Centers
  • 10.1.1. Community Health Centers
  • 10.1.2. Outpatient Clinics
• 10.2. Clinics
  • 10.2.1. Primary Care Clinics
  • 10.2.2. Specialty Clinics
• 10.3. Diagnostic Laboratories
  • 10.3.1. Commercial Laboratories
  • 10.3.2. Reference Laboratories
• 10.4. Hospitals
  • 10.4.1. Large Hospitals
  • 10.4.2. Small Hospitals

11. Helicobacter Pylori Diagnostics Market, by Technology

• 11.1. Invasive
  • 11.1.1. Culture
  • 11.1.2. Histology
  • 11.1.3. Rapid Urease Test
• 11.2. Noninvasive
  • 11.2.1. Antigen Test
  • 11.2.2. Breath Test
    • 11.2.2.1. Stool Antigen Test
    • 11.2.2.2. Urea Breath Test
  • 11.2.3. Molecular
  • 11.2.4. Serology

12. Helicobacter Pylori Diagnostics Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Helicobacter Pylori Diagnostics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Helicobacter Pylori Diagnostics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. F. Hoffmann-La Roche Ltd
  • 15.3.2. Abbott Laboratories
  • 15.3.3. Danaher Corporation
  • 15.3.4. bioMerieux SA
  • 15.3.5. Thermo Fisher Scientific Inc.
  • 15.3.6. Siemens Healthineers AG
  • 15.3.7. DiaSorin S.p.A.
  • 15.3.8. Bio-Rad Laboratories, Inc.
  • 15.3.9. Fujirebio Inc.
  • 15.3.10. Sekisui Medical Co., Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. HELICOBACTER PYLORI DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. HELICOBACTER PYLORI DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. HELICOBACTER PYLORI DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 262. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 263. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 264. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 267. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 268. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 269. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 270. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 271. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 272. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 273. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 274. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 275. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
• TABLE 276. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
• TABLE 277. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 278. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 20